Bio-Techne (TECH) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Bio-Techne (NASDAQ:TECH) by 28.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,662 shares of the biotechnology company’s stock after buying an additional 593 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Bio-Techne were worth $402,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of TECH. Dimensional Fund Advisors LP boosted its holdings in Bio-Techne by 3.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 198,911 shares of the biotechnology company’s stock worth $24,046,000 after buying an additional 6,660 shares during the last quarter. Bank of Montreal Can boosted its holdings in Bio-Techne by 83.6% in the 4th quarter. Bank of Montreal Can now owns 16,412 shares of the biotechnology company’s stock worth $2,126,000 after buying an additional 7,473 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Bio-Techne by 4.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 206,510 shares of the biotechnology company’s stock worth $26,754,000 after buying an additional 9,326 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in Bio-Techne by 51.1% in the 4th quarter. State of Alaska Department of Revenue now owns 9,399 shares of the biotechnology company’s stock worth $1,216,000 after buying an additional 3,180 shares during the last quarter. Finally, Conestoga Capital Advisors LLC boosted its holdings in Bio-Techne by 11.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 274,822 shares of the biotechnology company’s stock worth $35,603,000 after buying an additional 28,240 shares during the last quarter. Institutional investors own 98.22% of the company’s stock.

Several brokerages have recently weighed in on TECH. Zacks Investment Research upgraded Bio-Techne from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a report on Saturday, January 20th. BidaskClub upgraded Bio-Techne from a “buy” rating to a “strong-buy” rating in a report on Friday, March 16th. Deutsche Bank set a $163.00 target price on Bio-Techne and gave the stock a “buy” rating in a report on Thursday, March 1st. Leerink Swann set a $160.00 target price on Bio-Techne and gave the stock a “buy” rating in a report on Thursday, May 3rd. Finally, Craig Hallum restated a “buy” rating and set a $160.00 target price (up from $140.00) on shares of Bio-Techne in a report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Bio-Techne has a consensus rating of “Buy” and a consensus target price of $150.83.

Shares of Bio-Techne stock opened at $152.97 on Friday. The company has a market cap of $5.70 billion, a PE ratio of 44.73, a P/E/G ratio of 2.50 and a beta of 0.72. Bio-Techne has a 1-year low of $107.55 and a 1-year high of $154.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 4.30 and a current ratio of 5.55.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, May 2nd. The biotechnology company reported $1.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.07. The business had revenue of $164.00 million for the quarter, compared to analysts’ expectations of $163.43 million. Bio-Techne had a return on equity of 14.75% and a net margin of 18.29%. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.97 EPS. analysts expect that Bio-Techne will post 4.05 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 25th. Stockholders of record on Monday, May 14th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Friday, May 11th. Bio-Techne’s dividend payout ratio is currently 37.43%.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply